Expert discussions are underway on the lifting of bans on cannabis-derived drugs in Japan. The government is set to create the environment needed to allow for the utilization of such medicines by embracing this policy in its annual “honebuto” paper,…
REGULATORY
Diet Submission of Clinical Research Bill Expected for Next Year: Panel Member
A bill on the legal regulation of clinical research is expected to be tabled to the next ordinary Diet session, which will convene in January for a 150-day run, a member of a health ministry panel said on December 12.…
To read the full story
Related Article
- In a Flip-Flop, LDP Aims to Enact Clinical Research Bill in Current Diet Session
April 28, 2016
- Clinical Research Bill Won’t Be Enacted in Current Diet Session: LDP Health Panel Chief
March 30, 2016
- Difficult to Enact Clinical Research Bill in Current Diet Session: LDP Health Panel Chief
March 9, 2016
- Panel Reveals Final Report Calling for Legal Regulations for Clinical Research
December 12, 2014
- Panel Gives Green Light to Draft Report Calling for Legal Regulations for Clinical Research
November 27, 2014
REGULATORY
- FDA Philippines to Expedite Review Process of Japan-Approved Drugs
July 1, 2022
- AMED Employees’ Annual Pay Averaged 9.3 Million Yen in FY2021
July 1, 2022
- Ryukaikon to Assess Situation of Products Distributed by Single Wholesalers
July 1, 2022
- MHLW Panel to Discuss Cultivation of Cannabis for Use as Pharmaceutical Ingredient
July 1, 2022
- Survey Finds 11.7% of Wholesaler Transactions Negotiated through Proxies: MHLW
June 30, 2022
“The Tesla and SpaceX CEO sent an email to employees at both companies on Tuesday saying everyone must spend 40 hours per week in the office. ‘If you don’t show up, we will assume you have resigned. The more senior…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…